These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39062841)

  • 1. Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (
    Ambrodji A; Sadlon A; Amstutz U; Hoch D; Berger MD; Bastian S; Offer SM; Largiadèr CR
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062841
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(14):1-186. PubMed ID: 34484488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
    Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
    Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients.
    Pinheiro M; Peixoto A; Rocha P; Santos C; Escudeiro C; Veiga I; Porto M; Guerra J; Barbosa A; Pinto C; Arinto P; Resende A; Teixeira MR
    Pharmacogenet Genomics; 2023 Oct; 33(8):165-171. PubMed ID: 37611150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.
    Deenen MJ; Meulendijks D; Cats A; Sechterberger MK; Severens JL; Boot H; Smits PH; Rosing H; Mandigers CM; Soesan M; Beijnen JH; Schellens JH
    J Clin Oncol; 2016 Jan; 34(3):227-34. PubMed ID: 26573078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy.
    Wong BYL; Li Z; Raphael MJ; De Angelis C; Hwang DM; Fu L
    J Appl Lab Med; 2024 Mar; 9(2):295-304. PubMed ID: 38084968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
    Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
    Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.
    Medwid S; Wigle TJ; Kim RB
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
    Wigle TJ; Povitz BL; Medwid S; Teft WA; Legan RM; Lenehan J; Nevison S; Panuganty V; Keller D; Mailloux J; Siebring V; Sarma S; Choi YH; Welch S; Winquist E; Schwarz UI; Kim RB
    Clin Transl Sci; 2021 Jul; 14(4):1338-1348. PubMed ID: 33620159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
    García-Alfonso P; Saiz-Rodríguez M; Mondéjar R; Salazar J; Páez D; Borobia AM; Safont MJ; García-García I; Colomer R; García-González X; Herrero MJ; López-Fernández LA; Abad-Santos F
    Clin Transl Oncol; 2022 Mar; 24(3):483-494. PubMed ID: 34773566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
    Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
    PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score.
    Henricks LM; Lunenburg CA; Meulendijks D; Gelderblom H; Cats A; Swen JJ; Schellens JH; Guchelaar HJ
    Pharmacogenomics; 2015; 16(11):1277-86. PubMed ID: 26265346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
    Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
    BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
    Lunenburg CA; van Staveren MC; Gelderblom H; Guchelaar HJ; Swen JJ
    Pharmacogenomics; 2016 May; 17(7):721-9. PubMed ID: 27181275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Variation in miR-27a Is Associated with Fluoropyrimidine-Associated Toxicity in Patients with Dihydropyrimidine Dehydrogenase Variants after Genotype-Guided Dose Reduction.
    Medwid S; Wigle TJ; Ross C; Kim RB
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
    White C; Scott RJ; Paul C; Ziolkowski A; Mossman D; Fox SB; Michael M; Ackland S
    Clin Pharmacol Ther; 2022 Oct; 112(4):791-802. PubMed ID: 35607723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
    Morris SA; Moore DC; Musselwhite LW; Lopes KE; Hamilton A; Steuerwald N; Hanson SL; Larck C; Swift K; Smith M; Kadakia KC; Chai S; Hwang JJ; Patel JN
    Am J Health Syst Pharm; 2023 Sep; 80(19):1342-1349. PubMed ID: 37235983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants.
    Lunenburg CATC; Henricks LM; van Kuilenburg ABP; Mathijssen RHJ; Schellens JHM; Gelderblom H; Guchelaar HJ; Swen JJ
    Genes (Basel); 2018 Nov; 9(12):. PubMed ID: 30487465
    [No Abstract]   [Full Text] [Related]  

  • 20. Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).
    Milano G
    Scand J Clin Lab Invest Suppl; 2016; 245():S30-3. PubMed ID: 27454530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.